MA39337B1 - Modulateurs de pyrazines de gpr6 - Google Patents
Modulateurs de pyrazines de gpr6Info
- Publication number
- MA39337B1 MA39337B1 MA39337A MA39337A MA39337B1 MA 39337 B1 MA39337 B1 MA 39337B1 MA 39337 A MA39337 A MA 39337A MA 39337 A MA39337 A MA 39337A MA 39337 B1 MA39337 B1 MA 39337B1
- Authority
- MA
- Morocco
- Prior art keywords
- gpr6
- modulators
- pyrazine
- compounds
- methods
- Prior art date
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 2
- 101150014072 Gpr6 gene Proteins 0.000 title 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940294P | 2014-02-14 | 2014-02-14 | |
| PCT/US2015/015841 WO2015123533A1 (en) | 2014-02-14 | 2015-02-13 | Pyrazines modulators of gpr6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39337A1 MA39337A1 (fr) | 2017-10-31 |
| MA39337B1 true MA39337B1 (fr) | 2019-11-29 |
Family
ID=52598823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39337A MA39337B1 (fr) | 2014-02-14 | 2015-02-13 | Modulateurs de pyrazines de gpr6 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10000468B2 (enExample) |
| EP (1) | EP3105216B1 (enExample) |
| JP (1) | JP6484640B2 (enExample) |
| KR (1) | KR20160122215A (enExample) |
| CN (1) | CN106103421B (enExample) |
| AU (1) | AU2015218402B2 (enExample) |
| BR (1) | BR112016018418A2 (enExample) |
| CA (1) | CA2939382A1 (enExample) |
| CL (1) | CL2016002043A1 (enExample) |
| CR (1) | CR20160428A (enExample) |
| DO (1) | DOP2016000211A (enExample) |
| EA (1) | EA033861B1 (enExample) |
| EC (1) | ECSP16074207A (enExample) |
| ES (1) | ES2702205T3 (enExample) |
| GE (1) | GEP20186893B (enExample) |
| IL (1) | IL247140B (enExample) |
| MA (1) | MA39337B1 (enExample) |
| MX (1) | MX369857B (enExample) |
| MY (1) | MY184366A (enExample) |
| PE (1) | PE20170245A1 (enExample) |
| PH (1) | PH12016501613B1 (enExample) |
| UA (1) | UA117779C2 (enExample) |
| WO (1) | WO2015123533A1 (enExample) |
| ZA (1) | ZA201606077B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3105216B1 (en) * | 2014-02-14 | 2018-10-10 | Takeda Pharmaceutical Company Limited | Pyrazine modulators of gpr6 |
| EA202092442A3 (ru) | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR102317480B1 (ko) | 2017-03-23 | 2021-10-25 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| CN110520127B (zh) * | 2017-03-26 | 2023-05-16 | 武田药品工业株式会社 | 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺 |
| JOP20180057A1 (ar) * | 2017-06-15 | 2019-01-30 | Takeda Pharmaceuticals Co | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |
| WO2020063760A1 (en) | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| KR20230017787A (ko) * | 2020-04-30 | 2023-02-06 | 오레곤 헬스 앤드 사이언스 유니버시티 | Gpr39 단백질의 길항제 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4159331A (en) * | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| US5563142A (en) * | 1989-12-28 | 1996-10-08 | The Upjohn Company | Diaromatic substituted compounds as anti-HIV-1 agents |
| WO2001062765A2 (en) * | 1999-02-26 | 2001-08-30 | Arena Pharmaceuticals, Inc. | Small molecule modulators of g protein-coupled receptor six |
| US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
| NZ520484A (en) | 2000-02-16 | 2005-03-24 | Neurogen Corp | Substituted arylpyrazines that are modulators of CRF (corticotropin releasing factor) receptor and methods of treatment using them |
| BR0210102A (pt) * | 2001-06-01 | 2004-06-08 | Hoffmann La Roche | Derivados de pirimidina, triazina e pirazina como receptores de glutamato |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EA006707B1 (ru) | 2002-03-13 | 2006-02-24 | Янссен Фармацевтика Н. В. | Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы |
| JPWO2004054617A1 (ja) * | 2002-12-13 | 2006-04-20 | 協和醗酵工業株式会社 | 中枢疾患の予防および／または治療剤 |
| CN101693697A (zh) | 2003-07-30 | 2010-04-14 | 泽农医药公司 | 哌嗪衍生物和它们作为治疗剂的用途 |
| US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| US8580842B2 (en) * | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| CN1933838A (zh) * | 2004-02-12 | 2007-03-21 | 默克公司 | 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺 |
| ATE458730T1 (de) | 2004-04-13 | 2010-03-15 | Icagen Inc | Polycyclische pyrazine als kaliumionenkanal- modulatoren |
| GB0414438D0 (en) * | 2004-06-28 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| US20060199828A1 (en) * | 2005-03-04 | 2006-09-07 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| BRPI0611439A2 (pt) | 2005-05-13 | 2010-09-08 | Lexicon Pharmaceuticals Inc | compostos multicìclicos e métodos para uso dos mesmos |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| US8495335B2 (en) * | 2006-06-16 | 2013-07-23 | Raytheon Company | Data translation system and method |
| AU2009271414A1 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl GPR119 agonists and uses thereof |
| WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| MX2012013127A (es) | 2010-05-13 | 2012-11-30 | Amgen Inc | Compuestos heteroariloxiheterociclilo como inhibidores pde10. |
| SG185515A1 (en) * | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| US10252984B2 (en) * | 2011-10-27 | 2019-04-09 | Mayo Foundation For Medical Education And Research | Inhibiting G protein coupled receptor 6 kinase polypeptides |
| EP2882722B1 (en) * | 2012-08-13 | 2016-07-27 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as gpr6 modulators |
| TR201911140T4 (tr) | 2013-10-21 | 2019-08-21 | Merck Patent Gmbh | Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları. |
| EP3105216B1 (en) * | 2014-02-14 | 2018-10-10 | Takeda Pharmaceutical Company Limited | Pyrazine modulators of gpr6 |
-
2015
- 2015-02-13 EP EP15707836.1A patent/EP3105216B1/en active Active
- 2015-02-13 PE PE2016001477A patent/PE20170245A1/es unknown
- 2015-02-13 UA UAA201609102A patent/UA117779C2/uk unknown
- 2015-02-13 GE GEAP201514266A patent/GEP20186893B/en unknown
- 2015-02-13 ES ES15707836T patent/ES2702205T3/es active Active
- 2015-02-13 MA MA39337A patent/MA39337B1/fr unknown
- 2015-02-13 AU AU2015218402A patent/AU2015218402B2/en active Active
- 2015-02-13 KR KR1020167025131A patent/KR20160122215A/ko not_active Ceased
- 2015-02-13 EA EA201691632A patent/EA033861B1/ru unknown
- 2015-02-13 CR CR20160428A patent/CR20160428A/es unknown
- 2015-02-13 US US15/118,461 patent/US10000468B2/en not_active Expired - Fee Related
- 2015-02-13 JP JP2016551806A patent/JP6484640B2/ja not_active Expired - Fee Related
- 2015-02-13 MX MX2016010529A patent/MX369857B/es active IP Right Grant
- 2015-02-13 MY MYPI2016702927A patent/MY184366A/en unknown
- 2015-02-13 WO PCT/US2015/015841 patent/WO2015123533A1/en not_active Ceased
- 2015-02-13 CA CA2939382A patent/CA2939382A1/en not_active Abandoned
- 2015-02-13 CN CN201580013589.1A patent/CN106103421B/zh active Active
- 2015-02-13 BR BR112016018418A patent/BR112016018418A2/pt not_active Application Discontinuation
-
2016
- 2016-08-07 IL IL247140A patent/IL247140B/en active IP Right Grant
- 2016-08-12 PH PH12016501613A patent/PH12016501613B1/en unknown
- 2016-08-12 DO DO2016000211A patent/DOP2016000211A/es unknown
- 2016-08-12 CL CL2016002043A patent/CL2016002043A1/es unknown
- 2016-09-01 ZA ZA2016/06077A patent/ZA201606077B/en unknown
- 2016-09-14 EC ECIEPI201674207A patent/ECSP16074207A/es unknown
-
2018
- 2018-05-14 US US15/979,069 patent/US10273225B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| PH12018502535B1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| CO2017005218A2 (es) | Compuestos que modulan la enzima oxidorreductasa indolamina 2,3-dioxigenasa (ido) y composiciones que comprenden los compuestos” | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| CO2017005452A2 (es) | Compuestos que modulan la enzima oxidorreductasa indolamina 2,3-dioxigenasa (ido) y composiciones que comprenden tales compuestos | |
| EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
| MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
| BR112016028255A2 (pt) | agentes imunorreguladores | |
| MX388682B (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
| EA201691514A1 (ru) | Соединения | |
| PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| EA201892123A1 (ru) | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj | |
| MX383124B (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus. | |
| EA201790570A1 (ru) | Модуляторы р2х7 | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MX2018016290A (es) | Agente antidesgaste. | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| MX2019008375A (es) | Tiobenzoimidazol como fungicidas. | |
| MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
| MX2023001906A (es) | Diarilureas como moduladores alostericos de cannabinoide cb1. | |
| EA202090107A3 (ru) | Композиции, содержащие бактериальные штаммы |